-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ww94wzU0FXsDRPfowk1KHGlfpBQhIvxnkKAh2XbRKkTJLb/inXFxMxscgYqdnBuM +zSt68Uc+lYa7kOWXQST7g== 0001116502-07-000845.txt : 20070418 0001116502-07-000845.hdr.sgml : 20070418 20070418141700 ACCESSION NUMBER: 0001116502-07-000845 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070418 DATE AS OF CHANGE: 20070418 GROUP MEMBERS: AUGUSTINE LAWLOR GROUP MEMBERS: CHRISTOPHER MIRABELLI, PH.D. GROUP MEMBERS: ERIC AGUIAR, PH.D. GROUP MEMBERS: HAROLD R. WERNER GROUP MEMBERS: HEALTHCARE PARTNERS V, L.P. GROUP MEMBERS: HEALTHCARE PARTNERS VI, L.P. GROUP MEMBERS: HEALTHCARE PARTNERS VII, L.P. GROUP MEMBERS: HEALTHCARE VENTURES VI, L.P. GROUP MEMBERS: HEALTHCARE VENTURES VII, L.P. GROUP MEMBERS: JAMES H. CAVANAUGH, PH.D. GROUP MEMBERS: JOHN LITTLECHILD GROUP MEMBERS: WILLIAM CROUSE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ADVANCIS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001161924 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522208264 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79326 FILM NUMBER: 07773112 BUSINESS ADDRESS: STREET 1: 20425 SENECA MEADOWS PARKWAY CITY: GERMANTOWN STATE: MD ZIP: 20878 BUSINESS PHONE: (301) 944-6600 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHCARE VENTURES V L P CENTRAL INDEX KEY: 0001022423 IRS NUMBER: 223487780 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 44 NASSAU ST CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: 9089064600 MAIL ADDRESS: STREET 1: 44 NASSAU ST CITY: PRINCETON STATE: NJ ZIP: 08542 SC 13D/A 1 healthcare-sc13d_a.txt AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Advancis Pharmaceutical Corporation ------------------------------------ (Name of Issuer) Common Stock, par value $.01 per share -------------------------------------- (Title of Class of Securities) 00764L109 -------------- (CUSIP Number) Jeffrey B. Steinberg HealthCare Ventures LLC 44 Nassau Street Princeton, New Jersey 08542 (609) 430-3900 --------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 12, 2007 ------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [_]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. (Page 1 of 22) - --------------- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP NO. 00764L109 13D PAGE 2 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON HEALTHCARE VENTURES V, L.P. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 3,629,973 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 3,629,973 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,629,973 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.8% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* PN ________________________________________________________________________________ *SEE INSTRUCTIONS BEFORE FILLING OUT! * CUSIP NO. 00764L109 13D PAGE 3 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON HEALTHCARE PARTNERS V, L.P. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 3,629,973 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 3,629,973 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,629,973 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.8% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* PN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 4 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON HEALTHCARE VENTURES VI, L.P. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* WC ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 6,727,566 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 6,727,566 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,727,566 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.3% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* PN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 5 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON HEALTHCARE PARTNERS VI, L.P. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* WC ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 6,727,566 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 6,727,566 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,727,566 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.3% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* PN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 6 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON HEALTHCARE VENTURES VII, L.P. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* WC ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 2,754,293 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 2,754,293 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,754,293 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.82 ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* PN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 7 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON HEALTHCARE PARTNERS VII, L.P. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* WC ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 2,754,293 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 2,754,293 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,754,293 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.82% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* PN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 8 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON JAMES H. CAVANAUGH, PH.D. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA ________________________________________________________________________________ 7 SOLE VOTING POWER 82,073 NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 13,111,832 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING 82,073 __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 13,111,832 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,193,905 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 27.56% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* IN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 9 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON HAROLD R. WERNER ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA ________________________________________________________________________________ 7 SOLE VOTING POWER 82,073 NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 13,111,832 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING 82,073 __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 13,111,832 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,193,905 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 27.56% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* IN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 10 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON WILLIAM CROUSE ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 10,357,539 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 10,357,539 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,357,539 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 22.01% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* IN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 11 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON JOHN LITTLECHILD ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 13,111,832 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 13,111,832 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,111,832 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 27.41% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* IN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 12 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON CHRISTOPHER MIRABELLI, PH.D. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 13,111,832 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 13,111,832 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,111,832 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 27.41% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* IN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 13 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON AUGUSTINE LAWLOR ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 13,111,832 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 13,111,832 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,111,832 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 27.41% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* IN ________________________________________________________________________________ CUSIP NO. 00764L109 13D PAGE 14 OF 22 ________________________________________________________________________________ 1 NAME OF REPORTING PERSON SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON ERIC AGUIAR, PH.D. ________________________________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS* N/A ________________________________________________________________________________ 5 CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA ________________________________________________________________________________ 7 SOLE VOTING POWER NUMBER OF __________________________________________________________ 8 SHARED VOTING POWER SHARES 9,481,859 BENEFICIALLY __________________________________________________________ OWNED BY EACH 9 SOLE DISPOSITIVE POWER REPORTING __________________________________________________________ PERSON WITH 10 SHARED DISPOSITIVE POWER 9,481,859 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,481,859 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 19.82% ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON* IN ________________________________________________________________________________ Page 15 of 22 ITEM 1. SECURITY AND ISSUER. This Schedule 13D (this "Schedule 13D") relates to the common stock, par value $.01 per share (the "Common Stock"), of Advancis Pharmaceutical Corporation, a Delaware corporation (the "Issuer"). The address of the Issuer's principal executive office is 20425 Seneca Meadows Parkway, Germantown, Maryland 20876. ITEM 2. IDENTITY AND BACKGROUND. (a) The name of the reporting persons are HealthCare Ventures V, L.P. ("HCVV"), HealthCare Partners V, L.P. ("HCPV"), HealthCare Ventures VI, L.P. ("HCVVI"), HealthCare Partners VI, L.P. ("HCPVI"), HealthCare Ventures VII, L.P. ("HCVVII"), HealthCare Partners VII, L.P. ("HCPVII"), Drs. Cavanaugh, Mirabelli and Aguiar and Messrs. Werner, Crouse, Littlechild and, Lawlor (HCVV, HCPV, HCVVI, HCPVI, HCVVII, HCPVII, Drs. Cavanaugh, Mirabelli and Aguiar and Messrs. Werner, Crouse, Littlechild and, Lawlor are hereafter sometimes hereinafter referred to as the "Reporting Persons"). A copy of their agreement in writing to file this statement on behalf of each of them is attached hereto as Exhibit A.(1) HCVV, HCPV, HCVVI, HCPVI, HCVVII, and HCPVII, are limited partnerships organized and existing under the laws of the State of Delaware. HCPV is the General Partner of HCVV, HCPVI is the General Partner of HCVVI, and HCPVII is the General Partner of HCVVII. Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild, Crouse and Lawlor are the general partners of HCPV; Drs. Cavanaugh, Mirabelli, and Aguiar and Messrs. Werner, Littlechild, Crouse, and Lawlor are the general partners of HCPVI; and Drs. Cavanaugh, Mirabelli and Aguiar and Messrs Werner, Littlechild and Lawlor are the general partners of HCPVII. (b) The business address for HCVV, HCPV, HCVVI, HCPVI, HCVVII, HCPVII, Drs. Cavanaugh and Aguiar and Messrs. Werner and Crouse is 44 Nassau Street, Princeton, New Jersey 08542. The business address for Dr. Mirabelli and Messrs. Littlechild and Lawlor is 55 Cambridge Parkway, Suite 301, Cambridge, Massachusetts 02142. (c) Each of Drs. Cavanaugh, Mirabelli and Aguiar and Messrs. Werner, Crouse, Littlechild and Lawlor are general partners of various venture capital investment funds. The address for Drs. Cavanaugh and Aguiar and Messrs. Werner and Crouse is 44 Nassau Street, Princeton, New Jersey 08542 and the address for Dr. Mirabelli and Messrs. Littlechild and Lawlor is 55 Cambridge Parkway, Suite 301, Cambridge, Massachusetts 02142. (d) During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding. - -------------- (1) Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor are general partners of each of HCPV, HCPVI and HCPVII, the General Partners of HCVV, HCVVI and HCVVII, respectively, the record holders of the Issuer's securities. In addition, Dr. Aguiar is a general partner of each of HCPVI and HCPVII, the General Partners of each of HCVVI and HCVVII, the record holder of the Issuer's securities, and Mr. Crouse is a general partner of each of HCPV and HCPVI, the general partners of each of HCVV and HCVVI, respectively, the record holders of the Issuer's securities. Page 16 of 22 (e) During the last five years, none of the Reporting Persons were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) HCVV, HCPV, HCVVI, HCPVI, HCVVII and HCPVII are each limited partnerships formed and existing under the laws of the State of Delaware. Drs. Cavanaugh, Mirabelli and Aguiar and Messrs. Werner, Crouse, Littlechild and Lawlor are each individuals who are citizens of the United States. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. HCVVI and HCVVII acquired the Issuer's Common Stock and warrants to purchase Common Stock in a private placement of the Issuer (the "Private Placement") on April 12, 2007. The Common Stock and the warrants were sold in Units, each Unit consisting of one share of Common Stock and a warrant to purchase 0.75 shares of Common Stock (the "Units") for $2.36375 per Unit. HCVVI purchased 682,903 shares of the Issuer's Common Stock and warrants to purchase an additional 512,177 shares of the Issuer's Common Stock for an aggregate purchase price of $1,614,212. HCVVI used working capital to purchase the Units. HCVVII purchased 513,163 shares of the Issuer's Common Stock and warrants to purchase an additional 162,823 shares of the Issuer's Common Stock for an aggregate purchase price of $513,163. HCVVII used working capital to purchase the Units. ITEM 4. PURPOSE OF TRANSACTION. (a) Not Applicable. (b) Not Applicable (c) Not Applicable. (d) Not Applicable. (e) Not Applicable. (f) Not Applicable. (g) Not Applicable. (h) Not Applicable. (i) Not Applicable. (j) Not Applicable. Page 17 of 22 ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) HCVV directly beneficially owns 3,629,973 shares of the Common Stock of the Issuer representing 7.8% of the issued and outstanding shares of the Common Stock of the Issuer. HCVVI directly beneficially owns 6,727,566 shares of the Common Stock of the Issuer representing 14.3% of the issued and outstanding shares of the Common Stock of the Issuer consisting of (i) 6,215,389 shares of Common Stock; and (ii) immediately exercisable warrants to purchase 512,177 shares of the Issuer's Common Stock. HCVVII directly beneficially owns 2,754,293 shares of the Common Stock of the Issuer representing 5.82% of the issued and outstanding shares of the Common Stock of the Issuer consisting of (i) 1,975,892 shares of Common Stock; and (ii) immediately exercisable warrants to purchase 778,401 shares of the Issuer's Common Stock. HCPV may be deemed to indirectly beneficially own 3,629,973 shares of the Common Stock of the Issuer representing 7.8% of the issued and outstanding shares of the Common Stock of the Issuer as the General Partner of HCVV, the registered owner of the shares of Common Stock. HCPVI may be deemed to indirectly beneficially own 6,727,566 shares of the Common Stock of the Issuer representing 14.3% of the issued and outstanding shares of the Common Stock of the Issuer as the General Partner of HCVVI, the registered owner of the shares of Common Stock. HCPVII may be deemed to indirectly beneficially own 2,754,293 shares of the Common Stock of the Issuer representing 5.82% of the issued and outstanding shares of the Common Stock of the Issuer as the General Partner of HCVVII, the registered owner of the shares of Common Stock. Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor may be deemed to indirectly beneficially own 13,111,832 shares of the Common Stock of the Issuer representing 27.41% of the issued and outstanding shares of the Common Stock of the Issuer as General Partners of each of HCPV, HCPVI, and HCPVII, the General Partners of HCVV, HCVVI, and HCVVII, respectively. Dr. Aguiar may be deemed to indirectly beneficially own 9,481,859 shares of the Common Stock of the Issuer representing 19.82% of the issued and outstanding shares of the Common Stock of the Issuer as a General Partner of each of HCPVI and HCPVII, the General Partners of HCVVI and HCVVII, respectively. Mr. Crouse may be deemed to indirectly beneficially own 10,357,539 shares of the Common Stock of the Issuer representing 22.01% of the issued and outstanding shares of the Common Stock of the Issuer as a General Partner of HCPV and HCPVI, the General Partners of HCVV and HCVVI, respectively. In addition, Dr. Cavanaugh directly beneficially owns the 82,073 shares of the Common Stock of the Issuer held by him representing .18% of the issued and outstanding shares of the Common Stock of the Issuer consisting of (i) 42,073 shares directly beneficially owned by Dr. Cavanaugh; and (ii) immediately exercisable options to purchase 40,000 shares of the Issuer's Common Stock. Mr. Werner directly beneficially owns 82,073 shares of the Common Stock of the Issuer held by him representing .18% of the issued and outstanding shares of the Common Stock of the Issuer consisting of (i) 29,550 shares directly beneficially owned by Mr. Werner; and (ii) immediately exercisable options to purchase 40,000 shares of the Issuer's Common Stock. In addition, Mr. Werner indirectly beneficially owns 13,523 shares of the Common Stock of the Issuer representing .03% of the issued and outstanding shares of the Common Stock of the Issuer as the General Partner of the Werner Family Investment Limited Partnership (WFILP), the registered owner of the shares. Page 18 of 22 (b) HCVV and HCPV have the sole power to vote or dispose of all of the 3,629,973 shares of the Common Stock of the Issuer currently owned by them. HCVVI and HCPVI have the sole power to vote or dispose of all of the 6,727,566 shares of the Common Stock of the Issuer currently owned by them. HCVVII and HCPVII have the sole power to vote or dispose of all of the 2,754,293 shares of the Common Stock of the Issuer currently owned by them. Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor share the power to vote or direct the vote or the disposition of the 13,111,832 shares owned by HCVV, HCVVI, and HCVVII. Dr. Aguiar shares the power to vote or direct the vote or the disposition of 9,481,859 shares owned by HCVVI and HCVVII. Mr. Crouse shares the power to vote or direct the vote or disposition of 10,357,539 shares owned by HCVV and HCVVI. In addition, Mr. Werner has the sole power to vote or dispose of the 82,073 shares held directly by him or as General Partner of the WFILP and Mr. Cavanaugh has the sole power to vote or dispose of the 82,073 shares held directly by him. (c) During the past 60 days, HCVVI purchased the following shares of the Issuer's Common Stock and warrants to purchase Common Stock in the Private Placement: DATE OF TRANSACTION NO. OF SHARES PURCHASED PRICE PER UNIT ------------------- ----------------------- --------------- April 12, 2007 682,903 shares of Common $2.36375 Stock and warrants to purchase 512,177 shares of Common Stock During the past 60 days, HCVVII purchased the following shares of the Issuer's Common Stock and warrants to purchase Common Stock in the Private Placement: DATE OF TRANSACTION NO. OF SHARES PURCHASED PRICE PER UNIT ------------------- ----------------------- --------------- April 12, 2007 217,097 shares of Common $2.36375 Stock and warrants to purchase 162,823 shares of Common Stock (d) Not Applicable. (e) Not Applicable. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. Not Applicable ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit A - Joint Filing Agreement. Page 19 OF 22 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: April 17, 2007 HealthCare Ventures V, L.P., Princeton, New Jersey by its General Partner, HealthCare Partners V, L.P. By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Partners V, L.P. Princeton, New Jersey By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Ventures VI, L.P., Princeton, New Jersey by its General Partner, HealthCare Partners VI, L.P. By: /s/ Jeffrey Steinberg, Administrative Partner ---------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Partners VI, L.P. Princeton, New Jersey By: /s/ Jeffrey Steinberg, Administrative Partner ---------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Ventures VII, L.P., Princeton, New Jersey by its General Partner, HealthCare Partners VII, L.P. By: /s/ Jeffrey Steinberg, Administrative Partner ---------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Partners VII, L.P. Princeton, New Jersey By: /s/ Jeffrey Steinberg, Administrative Partner ---------------------------------------------- Administrative Partner
Page 20 OF 22 Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact --------------------------------------- Princeton, New Jersey James H. Cavanaugh, Ph.D. Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------- Harold R. Werner Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------- William Crouse Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------- John W. Littlechild Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------- Christopher Mirabelli, Ph.D. Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------- Augustine Lawlor Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------- Eric Aguiar, Ph.D. Page 21 of 22 EXHIBIT A AGREEMENT JOINT FILING OF SCHEDULE 13D The undersigned hereby consent to the joint filing by any of them of a Statement on Schedule 13D and any amendments thereto, whether heretofore or hereafter filed, relating to the securities of Advancis Pharmaceutical Corporation, Inc., and affirm that this Schedule 13D is being filed on behalf of each of the undersigned. Dated: April 17, 2007 HealthCare Ventures V, L.P., Princeton, New Jersey by its General Partner, HealthCare Partners V, L.P. By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Partners V, L.P. Princeton, New Jersey By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Ventures VI, L.P., Princeton, New Jersey by its General Partner, HealthCare Partners VI, L.P. By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Partners VI, L.P. Princeton, New Jersey By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner Dated: April 17, 2007 HealthCare Ventures VII, L.P., Princeton, New Jersey by its General Partner, HealthCare Partners VII, L.P. By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner
Page 22 of 22 Dated: April 17, 2007 HealthCare Partners VII, L.P. Princeton, New Jersey By: /s/ Jeffrey Steinberg, Administrative Partner --------------------------------------------- Administrative Partner Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------------- James H. Cavanaugh, Ph.D. Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------------- Harold R. Werner Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------------- William Crouse Dated: April , 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------------- John W. Littlechild Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------------- Christopher Mirabelli, Ph.D. Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------------- Augustine Lawlor Dated: April 17, 2007 By: /s/ Jeffrey Steinberg, Attorney-in-Fact Princeton, New Jersey --------------------------------------------- Eric Aguiar, Ph.D.
Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). -----END PRIVACY-ENHANCED MESSAGE-----